_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
Laurus will be incentivised for a portion of its development and commercialisation costs. CHAI will also provide technical and regulatory support to enable accelerated generic development
Incorporating multi-modality image guidance, Ethos therapy provides the ability to personalize the patient's treatment based on their anatomy and position at the time of treatment
The institute will provide the world’s first unique and comprehensive capability to predict, prevent, respond and to recover from future pandemics
Nipah virus (NiV) is an emerging zoonotic disease that causes severe disease in humans. Signs and symptoms range from asymptomatic to acute respiratory infection and fatal encephalitis
In comparison to traditional open-heart surgery, which involves opening up the chest by splitting the breastbone, da Vinci Xi's innovative technology allows for complex cardiovascular surgeries to be performed through smaller incisions and precise motion control
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
Subscribe To Our Newsletter & Stay Updated
